Accelerated BEP: A phase i trial of dose-dense BEP for intermediate and poor prognosis metastatic germ cell tumour

British Journal of Cancer

Volumn 105, Issue 6, 2011, Pages 766-772

  Rimmer, Y ^a   Chester, J ^b   Joffe, J ^b   Stark, D ^b   Shamash, J ^c   Powles, T ^c   White, J ^d   Wason, J ^e   Parashar, D ^e,f   Armstrong, G ^f   Mazhar, D ^a   Williams, M V ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^c ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^d BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^e MRC BIOSTATISTICS UNIT   (United Kingdom)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

accelerated; bleomycin; chemotherapy; dose density; germ cell tumours; growth factors

Indexed keywords

BLEOMYCIN; CISPLATIN; ETOPOSIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHAGIA; FATIGUE; FEBRILE NEUTROPENIA; FOLLOW UP; GERM CELL TUMOR; HEARING LOSS; HUMAN; KAPLAN MEIER METHOD; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RASH; SEPSIS; THROMBOCYTOPENIA; TINNITUS; TREATMENT RESPONSE; VOMITING;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CISPLATIN; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FILGRASTIM; HEARING LOSS; HUMANS; LUNG DISEASES; MALE; NEOPLASMS, GERM CELL AND EMBRYONAL; PROGNOSIS;

EID: 80052513808     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.309     Document Type: Article

References (39)

1. Ardizzoni A, Tjan-Heijnen VCG, Postmus PE (2002) Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European organisation for research and treatment of cancer-lung Cancer Group phase III trial-08923. J Clin Oncol 20: 3947-3955
2. Bissett D, Kunkeler L, Zwanenburg L, Paul J, Gray C, Swan IR, Kerr DJ, Kaye SB (1990) Long-term sequelae of treatment for testicular germ cell tumours. Br J Cancer 62: 655-659 (Pubitemid 20340585)
3. Bonilla L, Ben-Aharon I, Vidal L, Gafter-Gvili A, Leibovici L, Stemmer SM (2010) Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials. J Natl Cancer Inst 102: 1845-1854
4. Cancer Therapy Evaluation Program, National Cancer Institute (2006) Common Terminology Criteria for Adverse Events version 3.0 (CTCAE). http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ctcaev3. pdf
5. Cassidy J, Paul J, Soukop M, Habeshaw T, Reed NS, Parkin D, Kaye SB (1998) Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin. Cancer Chemother Pharmacol 41: 161-166 (Pubitemid 28096271)
6. Christian JA, Huddart AR, Norman A (2003) Intensive induction chemotherapy with CBOP/BEP in patients with with poor prognosis germ cell tumours. J Clin Oncol 21: 871-877 (Pubitemid 46606447)
7. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L (2003) Randomised trials of dose-dense versus conventionally scheduled and sequential (2003) versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of inter-group trial C 9741/Cancer and Leukemia group B trial 9471. J Clin Oncol 21: 1431-1439 (Pubitemid 46594092)
8. Collette L, Sylvester RJ, Stenning SP, Fossa SD, Mead GM, de Wit R, de Mulder PH, Neymark N, Lallemand E, Kaye SB (1999) Impact of the treating institution on survival of patients with "poor-prognosis" metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party. J Natl Cancer Inst 91: 839-846
9. Daugaard G, Rørth M (1986) High-dose cisplatin and VP-16 with bleomycin, in the management of advanced metastatic germ cell tumours. Eur J Cancer Clin Oncol 22: 477-485 (Pubitemid 16113807)
10. Daugaard G, Skoneczna I, Aass N, De Wit R, De Santis M, Dumez H, Marreaud S, Collette L, Lluch JR, Bokemeyer C, Schmoll HJ (2010) A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Group Germinal (EORTC 30974). Ann Oncol 22: 1054-1061
11. De Wit R, Roberts JT, Wilkinson PM, de Mulder PH, Mead GM, Fossä SD, Cook P, de Prijck L, Stenning S, Collette L (2001) Equivalence of 3 or 4 cycles of bleomycin, etoposide and cisplatin chemotherapy and of a 3-day or 5-day schedule in good-prognosis germ cell cancer: a randomised study of the European organisation for research and treatment of cancer. Genito-Urinary Tract Cancer Co-operative Group and the Medical Research Council. J Clin Oncol 19: 1629-1640 (Pubitemid 32230862)
12. De Wit R, Skoneczna IA, Daugaard KG, de Santis M, Garin A, Aass N, Witjes JA, Albers P, White J, Germa-Lluch JR, Osanto S, Marreaud S, Collette L (2011) A randomized phase III study comparing paclitaxel-BEP (T-BEP) to standard BEP in patients with in intermediate prognosis germ cell cancer (GCC): an intergroup study of EORTC, German TCSG/AUO, MRC, and Spanish GCC group (EORTC 30983). Ann Oncol 22(5): 1054-1061. ASCO abstract 4509
13. De Wit R, Stoter G, Sleijfer DT, Neijt JP, ten Bokkel Huinink WW, de Prijck L, Collette L, Sylvester R (1998) Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer. Br J Cancer 78: 828-832 (Pubitemid 28418322)
14. Fizazi K, Zelek L (2000) Is 'one cycle every three or four weeks' obsolete? A critical review of dose-dense chemotherapy in solid neoplasms. Ann Oncol 11: 133-149 (Pubitemid 30148726)
15. Fornier M, Norton L (2005) Dose-dense adjuvant chemotherapy for primary breast cancer. Breast Cancer Res 7: 64-69 (Pubitemid 40352672)
16. Fossa SD, de Wit R, Roberts JT, Wilkinson PM, de Mulder PH, Mead GM, Cook P, de Prijck L, Stenning S, Aaronson NK, Bottomley A, Collette L; European Organization for Research and Treatment of Cancer Genitourinary Group 30941; Medical Research Council Testicular Cancer Study Group TE20 (2003) Quality of life in good prognosis patients with metastatic germ cell cancer: a prospective study of the European Organization for Research and Treatment of Cancer Genitourinary Group/Medical Research Council Testicular Cancer Study Group (30941/TE20). J Clin Oncol 21: 1107-1118 (Pubitemid 46594141)
17. Fossa SD, Paluchowska B, Horwich A, Kaiser G, de Mulder PH, Koriakine O, van Oosterom AT, de Prijck L, de Wit R, EORTC GU Group (2005) Intensive induction chemotherapy with C-BOP/BEP for intermediate-and poor-risk metastatic germ cell tumours (EORTC trial 30948). Br J Cancer 93: 1209-1214 (Pubitemid 41679405)
18. Grimison PS, Thomson DB, Stockler M, Chatfield MD, Friedlander M, Gebski V, Boland AL, Houghton BB, Gurney H, Rosenthal M, Singhal N, Kichenadasse G, Wong SS, Lewis CR, Vasey PA, Toner GC (2011) Accelerated BEP for advanced germ cell tumors: an australian multi-center phase I/II trial. J Clin Oncol (2011 ASCO Annu Meet Proc (Post-Meeting Edition)) 29(15 Suppl): 4561.
19. Hamilton CR, Bliss JM, Horwich A (1989) The late effects of Cis-platinum on renal function. Eur J Cancer Clin Oncol 25: 185-189 (Pubitemid 19054818)
20. Hinton S, Catalano PJ, Einhorn LH, Nichols CR, David Crawford E, Vogelzang N, Trump D, Loehrer Sr PJ (2003) Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trial. Cancer 97: 1869-1875 (Pubitemid 36397260)
21. Horwich A, Brada M, Nicholls J (1989) Intensive induction chemotherapy for poor risk non-seminomatous germ cell tumours. Eur J Cancer 25: 177-184 (Pubitemid 19054817)
22. Horwich A, Dearnaley DP, Norman A, Nicholls J, Hendry WF (1994) Accelerated chemotherapy for poor prognosis germ cell tumours. Eur J Cancer 30A: 1607-1611 (Pubitemid 24355473)
23. International Germ Cell Cancer Collaborative Group (IGCCCG) (1997) International germ cell consensus classification: a prognosis factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15: 594-603
24. Kaye SB, Mead GM, Fossa S, Cullen M, deWit R, Bodrogi I, van Groeningen C, Sylvester R, Collette L, Stenning S, De Prijck L, Lallemand E, deMulder P (1998) Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor prognosis metastatic nonseminomatous germ cell tumour: a randomised Medical Research Council/European Organisation for Research and Treatment of Cancer Study. J Clin Oncol 16: 692-701 (Pubitemid 28135617)
25. Ladenstein R, Pötschger U, Le Deley MC, Whelan J, Paulussen M, Oberlin O, van den Berg H, Dirksen U, Hjorth L, Michon J, Lewis I, Craft A, Jürgens H (2010) Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. J Clin Oncol 28: 3284-3291
26. Lorigan P, Woll PJ, O'Brien ME, Ashcroft LF, Sampson MR, Thatcher N (2005) Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer. J Natl Cancer Inst 97: 666-674 (Pubitemid 40812630)
27. Macleod PM, Tyrell CJ, Keeling DH (1988) The effect of cisplatin on renal function in patients with testicular tumours. Clin Radiol 39: 190-192 (Pubitemid 18066550)
28. Motzer RJ, Nichols CJ, Margolin KA, Bacik J, Richardson PG, Vozelgang NJ, Bajorin DF, Lara PN, Einhorn L, Mazumdar M, Bosl GJ (2007) Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol 25: 247-256 (Pubitemid 350003012)
29. Nichols CR, Catalano PJ, Crawford ED, Vogelzang NJ, Einhorn LH, Loehrer PJ (1998) Randomised comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumours: an Eastern Cooperative Oncology Group, Southwest Oncology Group and Cancer and Leukaemia Group B Study. J Clin Oncol 16: 1287-1293 (Pubitemid 28175741)
30. Nichols CR, Williams SD, Loehrer PJ, Greco FA, Crawford ED, Weetlaufer J, Miller ME, Bartolucci A, Schacter L, Einhorn LH (1991) Randomised study of Cisplatin dose intensity in poor-risk germ cell tumours: South Eastern Cancer Study Group and South West Oncology Group Protocol. J Clin Oncol 7: 1163-1172
31. O'Sullivan JM, Huddart RA, Norman AR, Nicholls J, Dearnaley DP, Horwich A (2003) Predicting the risk of bleomycin lung toxicity in patients with germ cell tumours. Ann Oncol 14: 91-96 (Pubitemid 36150265)
32. Osanto S, Bukman A, Van Hoek F, Sterk PJ, De Laat JA, Hermans J (1992) Long-term effects of chemotherapy in patients with testicular cancer. J Clin Onc 10(4): 574-579
33. Pfreundschuh M, Trümper L, Kloess M, Schmits R, Feller AC, Rübe C, Rudolph C, Reiser M, Hossfeld DK, Eimermacher H, Hasenclever D, Schmitz N, Loeffler M, German High-Grade Non-Hodgkin's Lymphoma Study Group (2004) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 104: 634-641 (Pubitemid 38970554)
34. Saxman SB, Nichols CR, Einhorn LH (1997) Pulmonary toxicity in patients with advanced-stage germ cell tumours receiving bleomycin with and without granulocyte colony stimulating factor (1997). Chest 111: 657-660 (Pubitemid 27132942)
35. Schmoll HJ, Kollmannsberger C, Metzner B, Hartmann JT, Schleucher N, Schöffski P, Schleicher J, Rick O, Beyer J, Hossfeld D, Kanz L, Berdel WE, Andreesen R, Bokemeyer C, German Testicular Cancer Study Group (2003) Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group. J Clin Oncol 21: 4083-4091 (Pubitemid 46606174)
36. Shamash J, Powles T, Ansell W, Berney D, Stebbing J, Mutsvangwa K, Wilson P, Asterling S, Liu S, Wyatt P, Joel SP, Oliver RT (2007b) GAMEC-a new intensive protocol for untreated poor prognosis and relapsed or refractory germ cell tumours. Br J Cancer 97: 308-314 (Pubitemid 47196738)
37. Shamash J, Powles T, Mutsvangwa K, Wilson P, Ansell W, Walsh E, Berney D, Stebbing J, Oliver T (2007a) A phase II study using a topoisomerase I-based approach in patients with multiply relapsed germ-cell tumours. Ann Oncol 18: 925-930 (Pubitemid 47061293)
38. Thatcher N, Girling DJ, Hopwood P, Sambrook RJ, Qian W, Stephens RJ (2000) Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose intensity of chemotherapy with granular site colony-stimulating factor support: results British Medical Research Council multicentre randomised trial. J Clin Oncol 18: 395-404 (Pubitemid 30056430)
39. Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ (1987) Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. New Eng J Med 316: 1435-1440 (Pubitemid 17079090)